Physicians' Academy for Cardiovascular Education

Inflammation and CV risk: Beyond statins in the treatment of atherosclerosis

3' education - Mar. 8, 2016 - Boston, MA, USA - Paul M Ridker

Video navigation menu

  • Interindividual variability in response to statins 0:09
  • Targeting inflammation to lower residual risk 2:14
  • Reducing hsCRP is as important as reducing LDL-c to lower vascular events 3:55
  • The NLRP3 inflammasome - central to the postulated mechanism underlying inflammation in CV disease 4:50
  • Targeting the IL-1beta - IL-6 pathway in two large ongoing clinical trials 5:51
  • The fundamental question: 'Will lowering inflammation lower CV risk in the absence of change in LDL-c level?' 6:46

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: